EP Wealth Advisors LLC Invests $811,000 in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• EP Wealth Advisors acquired 1,301 Regeneron shares worth approximately $811,000 in the second quarter. Institutional investors collectively own 83.31% of REGN, with major holders including BlackRock and Vanguard.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $801.70. Regeneron recently exceeded quarterly expectations, reporting $14.29 in earnings per share and $4.29 billion in revenue.
• Regeneron announced FDA approval for Pasatru, expanding its rare-disease portfolio, while also pursuing its olatorepatide obesity-treatment program. The company faces legal and reputational risks related to investor litigation alleging misleading disclosures about its Fianlimab-Libtayo melanoma trial.

EP Wealth Advisors LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,301 shares of the biopharmaceutical company's stock, valued at approximately $811,000.

Other large investors also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $5,682,636,000. Vanguard Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company's stock valued at $7,004,838,000 after purchasing an additional 26,884 shares during the period. Dodge & Cox lifted its stake in shares of Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company's stock valued at $3,547,791,000 after purchasing an additional 45,513 shares during the period. Franklin Resources Inc. boosted its position in shares of Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company's stock valued at $1,975,990,000 after purchasing an additional 106,861 shares in the last quarter. Finally, Nuveen LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock valued at $1,551,858,000 after acquiring an additional 835,240 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on REGN shares. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating on the stock in a research note on Monday, May 18th. Benchmark upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Guggenheim increased their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Finally, Wall Street Zen raised shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 15th. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $801.70.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $834.04 on Monday. The company has a market cap of $85.87 billion, a PE ratio of 20.61, a price-to-earnings-growth ratio of 1.42 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $847.00. The business has a 50 day moving average price of $697.09 and a 200-day moving average price of $716.46. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $12.81 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.29%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director owned 603 shares of the company's stock, valued at $482,400. This represents a 39.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares of the company's stock, valued at $1,362,400. The trade was a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock worth $1,090,030 in the last ninety days. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source